Clinical Trial

IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer

Name: IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer — clinical trial record (NCT07402070)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a Phase 2 study to evaluate the safety, and efficacy of IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer.

Trial Details

NCT Number	NCT07402070
Lead Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Conditions	Resectable Stage II-III Non-small Cell Lung Cancer
Enrollment	10 participants
Start Date	2026-02-04
Primary Completion	2026-12-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-02-11